## **Revised Supplementary Files**

Revised supplementary file1: revised supplementary figures 1-4 Revised supplementary file2: revised supplementary dataset

## Mirtazapine exerts astrocyte-mediated dopaminergic neuroprotection

Ryo Kikuoka<sup>1</sup>, Ikuko Miyazaki<sup>1</sup>, Natsuki Kubota<sup>1</sup>, Megumi Maeda<sup>1</sup>, Daiki Kagawa<sup>1</sup>, Masaaki Moriyama<sup>1</sup>, Asuka Sato<sup>1</sup>, Shinki Murakami<sup>1</sup>, Yoshihisa Kitamura<sup>2</sup>, Toshiaki Sendo<sup>2</sup>, Masato Asanuma<sup>1, \*</sup>

 <sup>1</sup> Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
<sup>1</sup> Department of Clinical Pharmacy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

\*Corresponding author: Prof. Masato Asanuma, MD, PhD, Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan Tel: +81-86-235-7096

## Mirtzapine exerts astrocyte-mediated dopaminergic neuroprotection

Figure number		group		Pvalua	E/t Values	Test type
le	TH positive cells	group		p = 0.00015	F(5.35) = 7.241	rest type
	control side	vehicle	6	p 0.00015	1 (3,33) 7.241	-
	lesioned side	mirtazapine (5 mg/kg)	6	p = 0.821 (vs. same side of vehicle-treated group)		one-way ANOVA followed by post-hoc Fisher's LSD test
		mirtazapine (16 mg/kg)	6	p = 0.0819 (vs. same side of vehicle-treated group)		
		vehicle	6	p = 0.001 (vs. control side of each group) p = 0.0741 (vs. same side of vehicle-treated group)		
		mirtazapine (5 mg/kg)	6	p = 0.0515 (vs. control side of each group) p = 0.0515 (vs. control side of each group)		
				p = 0.0007 (vs. same side of vehicle-treated group)		
		mirtazapine (16 mg/kg)	6	p = 0.0603 (vs. same side of mirtazapine (5 mg/kg)-treated group)		
			-	p = 0.1908 (vs. control side of each group)		
	ТН			p < 0.0001	F (5,31) = 10.339	
	control side	vehicle	5			one-way ANOVA followed by post-hoc Fisher's LSD test
	lesioned side	mirtazapine	5	p = 0.1108(vs. same side of vehicle-treated group) p = 0.165 (vs. same side of vehicle treated group)		
1f		vehicle	5	p = 0.0009 (vs. control side of each group) p = 0.0009 (vs. control side of each group)	_	
		mirtazapine	5	p = 0.0042 (vs. same side of vehicle-treated group)		
			-	p = 0.0323 (vs. control side of each group) p = 0.870 (vs. comparide of value treated group)		
		mirtazapine + WAY	6	p = 0.0043 (vs. same side of ventcie-treated group) p = 0.0043 (vs. same side of mirtazapine-treated group)		
				p = 0.0002 (vs. control side of each group)		
	\$100B			n < 0.0001	F(535) = 12377	-
	santral side		(	p - 0.0001	1 (0,00) 12:077	
	control side	mirtazapine (5 mg/kg)	6	p = 0.0026 (vs. same side of vehicle-treated group)		
		mirtazapine (16 mg/kg)	6	p = 0.0181 (vs. same side of vehicle-treated group)		
	lesioned side	vehicle	6	p = 0.0072 (vs. control side of each group) = 0.022 (vs. control side of each group)		
		mirtazapine (5 mg/kg)	6	p = 0.023 (vs. same side of venicle-treated group) p = 0.0554 (vs. control side of each group)		
		mirtazanine (16 mg/kg)	6	p = 0.0001 (vs. same side of vehicle-treated group)		
2b		initiazapine (10 mg/kg)	0	p < 0.0001 (vs. control side of each group)		one-way ANOVA followed by
	S100β & MT			p < 0.0001	F (5,35) = 16.075	post-noc Fisher's LSD test
	control side	vehicle	6			-
		mirtazapine (5 mg/kg)	6	p = 0.0025 (vs. same side of vehicle-treated group)		
	logionad side	mirtazapine (16 mg/kg)	6	p = 0.0581 (vs. same side of vehicle-treated group) p = 0.0024 (vs. same side of each group)	_	
	lesioned side	venicie	0	p = 0.024 (vs. control side of each group) p = 0.021 (vs. same side of vehicle-treated group)		
		mirtazapine (5 mg/kg)	6	p = 0.0202 (vs. control side of each group)		
		mirtazapine (16 mg/kg)	6	p < 0.0001 (vs. same side of vehicle-treated group)		
			-	p < 0.0001 (vs. control side of each group)		
	GFAP			p < 0.0001	F (5,35) = 32.815	
	control side	vehicle	6			
		mirtazapine (5 mg/kg)	6	p = 0.273 (vs. same side of vehicle-treated group) p = 0.501 (vs. same side of vehicle treated group)		
	lesioned side	vehicle	6	p = 0.001 (vs. same side of vehicle-dealed group) p = 0.0003 (vs. control side of each group)	_	one-way ANOVA followed by post-hoc Fisher's LSD test
		mirtazapine (5 mg/kg)	6	p = 0.0065 (vs. same side of vehicle-treated group)		
		initial aprile (5 mg/ng)	0	p < 0.0001 (vs. control side of each group) p < 0.0001 (vs. come side of vabiale treated group)		
		mirtazapine (16 mg/kg)	6	p < 0.0001 (vs. same side of venere-ireated group) p < 0.0001 (vs. control side of each group)		
2d	CEAD & MT			n < 0.0001	E (5 25) - 22 884	
				p · 0.0001	1 (0,00) 02.001	
	control side	vehicle	6			
		mirtazapine (5 mg/kg)	6	p = 0.3295 (vs. same side of vehicle-treated group)		
	lesioned side	mirtazapine (16 mg/kg)	6	p = 0.495 (vs. same side of vehicle-treated group)	_	
		venicie	0	p = 0.005 (vs. control side of each group) p = 0.005 (vs. same side of vehicle-treated group)		
		mirtazapine (5 mg/kg)	6	p < 0.0001 (vs. control side of each group)		
		mirtazapine (16 mg/kg)	6	p < 0.0001 (vs. same side of vehicle-treated group)		
				p < 0.0001 (vs. control side of each group)		
	MT density			p = 0.00089	F (5,35) = 5.629	
	control side	vehicle	6			one-way ANOVA followed by post-hoc Fisher's LSD test
		mirtazapine (5 mg/kg)	6	p = 0.0554 (vs. same side of vehicle-treated group)		
2f	lesioned side	mirtazapine (16 mg/kg)	6	p = 0.458 (vs. same side of vehicle-treated group)		
21		vehicle	6	p = 0.13 (vs. control side of each group) p = 0.215 (vs. comparing side of value la transmission)		
		mirtazapine (5 mg/kg)	6	p = 0.513 (vs. same side of ventere freated group) p = 0.564 (vs. control side of each group)		
				p = 0.00027 (vs. same side of vehicle-treated group)		
		mirtazapine (16 mg/kg)	6	p = 0.0003 (vs. control side of each group)		
			-	p = 0.0318 (vs. same side of mirtazapine (5 mg/kg)-treated group)		
	S100β			p = 0.0406	F (2,15) = 4.14	
		vehicle	5			one-way ANOVA followed by
		mirtazapine	5	p = 0.0142 (vs. vehicle-treated group)		post-hoc Fisher's LSD test
3b		mistoronic - + WAX		p = 0.317 (vs. vehicle-treated group)		
		mirtazapine + wA i	0	p = 0.0774 (vs. mirtazapine-treated group)		
	S100β & MT			p = 0.00717	F (2,15) = 7.395	
		vehicle	5			
		mirtezanine	-	$\mathbf{p} = 0.0249$ (vs. vehicle-treated group)		nost-hoc Fisher's I SD test
		init azapite	,	p = 0.774 (vs. vehicle treated group)		Free cost inter a role top test
		mirtazapine + WAY	6	p = 0.274 (vs. venicie-reated group) p = 0.0022 (vs. mirtazapine-treated group)		
3d	GEAP			p = 0.207	E (2 15) - 1 774	
	JIAI			p 0.207	1 (2,13) = 1.//0	
		vehicle	5			post-hoc Fisher's LSD test
		mirtazapine	5			Free cost inter a role top test
		mirtazapine + WAY	6			
	GFAP & MT			p = 0.00109	F (2,15) = 12.073	
		vehicle	5		+	
		mirtozonico	-	$\mathbf{p} = 0.0141$ (ve vahiola tracted aroun)		one-way ANOVA followed by
		mirtazapine	2	p = 0.0141 (vs. venicie-treated group)		post-hoc Fisher's LSD test
		mirtazapine + WAY	6	p = 0.0/38 (vs. vehicle-treated group) p = 0.0003 (vs. mirtazapipe-treated group)		
				p 0.0005 (vs. nn uzapine-iteateu group)	-	
	M1 density			p = 0.00067	F (2,15) = 13.496	
3f		vehicle	5			one-way ANOVA followed by
		mirtazapine	5	p = 0.005 (vs. vehicle-treated group) p = 0.132 (vs. vehicle-treated group)		post-noc Fisher's LSD test
		mirtazapine + WAY	6	p = 0.0002 (vs. mirtazapine-treated group)		

	TH positive cells			p < 0.0001	F (7,23) = 43.986	
4a	control	6-OHDA (0 μM) 6 OHDA (10 μM)	3	n = 0.0011 (see 6 OHDA (0.0M) group)		
		6-OHDA (10 μM) 6-OHDA (25 μM)	3	p = 0.0011 (vs. 6-OHDA (0 µM) group) p < 0.0001 (vs. 6-OHDA (0 µM) group)		
	Mirtazapine (10 µM)	6-OHDA (50 μM) 6-OHDA (0 μM)	3	p < 0.0001 (vs. 6-OHDA (0 μM) group)	-	one-way ANOVA followed by post-hoc Fisher's LSD test
		6-OHDA (10 μM)	3	p = 0.009 (vs. Mirtazapine (10 $\mu$ M)+6-OHDA (0 $\mu$ M) group) p = 0.756 (vs. control+6-OHDA (10 $\mu$ M) group)		pose-lice i islici s 200 lest
		6-OHDA (25 μM)	3	p = 0.0002 (vs. Mirtazapien (10µM)+6-OHDA (0 µM) group) p = 0.599 (vs. control+6-OHDA (25 µM) group)		
		6-OHDA (50 μM)	3	$p < 0.0001$ (vs. Mirtazapine (10 $\mu$ M)+6-OHDA (0 $\mu$ M) group) $p = 0.404$ (vs. control+6-OHDA (50 $\mu$ M) group)		
	TH positive cells			p < 0.0001	F (7,23) = 54.075	
	control	6-OHDA (0 μM)	3			
		6-OHDA (50 μM) 6-OHDA (100 μM)	3	$p = 0.002$ (vs. 6-OHDA (0 $\mu$ M) group) $p \le 0.0001$ (vs. 6-OHDA (0 $\mu$ M) group)		one-way ANOVA followed by post-hoc Fisher's LSD test
4b	Mirtazapine (10 µM)	6-OHDA (150 μM)	3	$p < 0.0001$ (vs. 6-OHDA (0 $\mu$ M) group) $p < 0.0001$ (vs. 6-OHDA (0 $\mu$ M) group)		
40		6-OHDA (0 μM)	3	$p = 0.225$ (vs. Mirtazapine (10 $\mu$ M)+6-OHDA (0 $\mu$ M) group)		
		6-OHDA (50 μM)	3	$p = 0.0003$ (vs. control+6-OHDA (50 $\mu$ M) group) $p = 0.0005$ (vs. Mirtazapine (10 $\mu$ M)+6-OHDA (0 $\mu$ M) group)		
		6-OHDA (100 μM)	3	$p < 0.0001$ (vs. control+6-OHDA (100 $\mu$ M) group) $p < 0.0001$ (vs. distargaping (10 $\mu$ M) Group) $p < 0.0001$ (vs. Mistargaping (10 $\mu$ M) Group)		
		6-OHDA (150 μM)	3	$p = 0.0275$ (vs. control+6-OHDA (150 $\mu$ M) group)		
	TH positive cells			p < 0.0001	F (7,35) = 93.897	
	control	control WAY100635 (10 nM)	4	$p = 0.612$ (vs. control+6-OHDA (0 $\mu$ M) group)		
		Mirtazapine (10 µM)	4	$p = 0.795$ (vs. control+6-OHDA (0 $\mu$ M) group)		
		WAY100635 + mirtazapine	6	$p = 0.936$ (vs. control+6-OHDA (0 $\mu$ M) group)		
4c	6-OHDA (100 μM)	control	4	p < 0.0001 (vs. control+6-OHDA (0 μM) group) p < 0.0001 (vs. WAY+6-OHDA (0μM) group)		one-way ANOVA followed by post-hoc Fisher's LSD test
		WAY100635 (10 nM)	4	$p = 0.0108$ (vs. control+6-OHDA (100 $\mu$ M) group) $p = 0.0003$ (vs. Mirtaganine (10 $\mu$ M)+6-OHDA (100 $\mu$ M) group)		
		Mirtazapine (10 µM)	4	p = 0.0001 (vs. Mirtazapine (10 µM) to OHDA (100 µM) group) p < 0.0001 (vs. Mirtazapine (10 µM)+6-OHDA (0 µM) group)		
				$p < 0.0001$ (vs. control+6-OHDA (100 $\mu$ M) group) $p < 0.0001$ (vs. WAY + mirtazapine (10 $\mu$ M)-6OHDA (0 $\mu$ M) group)		
		WAY100635 + mirtazapine	6	$p = 0.0479$ (vs. control+6-OHDA (100 $\mu$ M) group) $p < 0.0001$ (vs. Mirtazapine (10 $\mu$ M)+6-OHDA (100 $\mu$ M) group)		
	number of astrocyte			p = 0.714	F (3,95) = 0.454	
50		control	24			one-way ANOVA followed by
54		Mirtazapine (2.5 µM)	24			post-hoc Fisher's LSD test
		Mirtazapine (5 µM) Mirtazapine (10 µM)	24 24			
	number of astrocyte			p = 0.0144	F (7,79) = 3.747	one-way ANOVA followed by post-hoc Fisher's LSD test
5b		control-NCM Mir (2.5 µM)-NCM	20 20	p = 0.227 (vs. control-NCM group)		
		Mir (5 µM)-NCM Mir (10 µM)-NCM	20 20	p = 0.003 (vs. control-NCM group) p = 0.0147 (vs. control-NCM group)		
	number of astrocyte			p = 0.00297	F (3,95) = 4.992	one-way ANOVA followed by post-hoc Fisher's LSD test
50		control-NCM	24			
50		control-NCM + WAY Mir (10 µM)-NCM	24 24	p = 0.6/8 (vs. control-NCM group) p = 0.0026 (vs. control-NCM group)		
		Mir (10 µM)-NCM + WAY	24	p = 0.188 (vs. control-NCM group) p = 0.0804 (vs. Mir-NCM group)		
	number of MT-			p = 0.47	F (3,71) = 0.851	one-way ANOVA followed by post-hoc Fisher's LSD test
6b	minunopositive cen	control	18			
		Mirtazapine (2.5 µM) Mirtazapine (5 µM)	18			
	MT density	Mirtazapine (10 µM)	18	n - 0.7	E(2.71) = 0.475	
60		control	18	p 0.7	1 (5,71) 0.475	one-way ANOVA followed by
		Mirtazapine (2.5 µM) Mirtazapine (5 µM)	18 18			post-hoc Fisher's LSD test
	number of MT	Mirtazapine (10 µM)	18			
6e	immunopositive cell			p < 0.0001	F (3,53) = 33.796	
		control-NCM Mir (2.5 μM)-NCM	16 13	p < 0.0001 (vs. control-NCM group)		one-way ANOVA followed by post-hoc Fisher's LSD test
		Mir (5 µM)-NCM Mir (10 µM)-NCM	11 14	p < 0.0001 (vs. control-NCM group) p < 0.0001 (vs. control-NCM group)		
6f	MT density			p = 0.00178	F (3,53) = 5.785	
		control-NCM	16			one-way ANOVA followed by post-hoc Fisher's LSD test
		Mir (2.5 µM)-NCM Mir (5 µM)-NCM	13	p = 0.0046 (vs. control-NCM group) p = 0.0011 (vs. control-NCM group) p = 0.0014 (vs. control-NCM group)		
6h	number of MT-	Міг (10 µм)-NCM	14	p = 0.0014 (vs. control-NCM group) n < 0.0001	F(3 118) = 8 177	one-way ANOVA followed by post-hoc Fisher's LSD test
	immunopositive cell	control-NCM	30			
		control-NCM + WAY	29	p = 0.401 (vs. control-NCM group) p < 0.0001 (vs. control NCM group)		
		Mir (5 µM)-NCM	30	p < 0.0001 (vs. control-NCM group) p = 0.0419 (vs. control-NCM group)		
	New York		50	p = 0.0107 (vs. Mir-NCM group)	E (2.100) - 2.55	
6i	M I density	control NCM + control	25	p = 0.0159	F (3,102) = 3.609	1
		control-NCM + WAY	25	p = 0.307 (vs.control-NCM group)		one-way ANOVA followed by post-hoc Fisher's LSD test
		Mir (5 µM)-NCM + control	26	p = 0.0406 (vs. control-NCM group) p = 0.763 (vs. control-NCM group)		post not risher till bib test
Ì	1	(5 µm)-ivCivi + wA1	20	p = 0.0182 (vs. Mir-NCM group)	1	

## Mirtzapine exerts astrocyte-mediated dopaminergic neuroprotection

	TH positive cells			p < 0.0001	F (5,35) = 10.88	
7a	control 6-OHDA (50 μM)	control-NCM-ACM Mir-NCM-ACM Mir-NCM + WAY 106635-ACM control-NCM-ACM Mir-NCM-ACM Mir-NCM + WAY 100635-ACM	6 6 6 6	$ \begin{split} p &= 0.666 \ (vs. \ control-NCM-ACM+6-OHDA (0 \ \mu M) \ group) \\ p &= 0.688 \ (vs. \ control-NCM-ACM+6-OHDA (0 \ \mu M) \ group) \\ p &= 0.0001 \ (vs. \ ontrol-NCM-ACM+6-OHDA (0 \ \mu M) \ group) \\ p &= 0.00213 \ (vs. \ ontrol-NCM-ACM+6-OHDA (0 \ \mu M) \ group) \\ p &= 0.0022 \ (vs. \ Mir-NCM - ACM+6-OHDA (0 \ \mu M) \ group) \\ p &= 0.358 \ (vs. \ control-NCM-ACM+6-OHDA (50 \ \mu M) \ group) \\ p &= 0.358 \ (vs. \ ontrol-NCM-ACM+6-OHDA (50 \ \mu M) \ group) \\ p &= 0.358 \ (vs. \ ontrol-NCM-ACM+6-OHDA (50 \ \mu M) \ group) \\ p &= 0.155 \ (vs. \ Mir-NCM-ACM+6-OHDA (50 \ \mu M) \ group) \\ \end{split}$		one-way ANOVA followed by post-hoc Fisher's LSD test
7ь	MT-1 concentration			p = 0.00403	F (1,11) = 13.782	one-way ANOVA followed by post-hoc Fisher's LSD test
		control-NCM-ACM Mir-NCM-ACM	6 6	p = 0.004 (vs. control-NCM-ACM)		
	TH positive cells			p < 0.0001	F (5,35) = 36.334	
7c	control 6-OHDA (50 μM)	control-NCM-ACM Mir-NCM-ACM Mir-NCM-ACM + MT-1/2 Ab control-NCM-ACM Mir-NCM-ACM Mir-NCM-ACM	6 6 6 6	p = 0.758 (vs. control-NCM-ACM+6-OHDA (0 μM) group) p = 0.874 (vs. control-NCM-ACM+6-OHDA (0 μM) group) p < 0.0001 (vs. control-NCM-ACM+6-OHDA (0 μM) group) p < 0.0001 (vs. dnir-NCM-ACM+6-OHDA (0 μM) group) p = 0.0347 (vs. control-NCM-ACM+6-OHDA (0 μM) group) p < 0.0001 (vs. Mir-NCM-ACM+6-OHDA (0 μM) group) p = 0.745 (vs. control-NCM-ACM+6-OHDA (50 μM) group) p = 0.0145 (vs. Mir-NCM-ACM+6-OHDA (50 μM) group) p = 0.0160 (vs. Mir-NCM-ACM+6-OHDA (50 μM) group)		one-way ANOVA followed by post-hoe Fisher's LSD test

Figure number		group		Puelue	E/t Values	Test time
Figure frumber		group		i value	F/t values	Test type
supplemental fig. 2b	S100β			p = 0.815	F (1,21) = 0.0558	one-way ANOVA followed by
		vehicle mirtazanine (16 mg/kg)	5			post-hoc Fisher's LSD test
	S100β & MT	in the first (is the tag)		p = 0.0469	F (1,21) = 4.4483	one-way ANOVA followed by post-hoc Fisher's LSD test
		vehicle mirtazapine (16 mg/kg)	5 6	p = 0.0469 (vs. vehicle-treated group)		
	S100β			p = 0.00016	F (5,35) = 7.173	
	control side lesioned side	vehicle mirtazapine (5 mg/kg) mirtazapine (16 mg/kg) vehicle	6 6 6	p p = 0.275 (vs. same side of vehicle-treated group) p = 0.0008 (vs. same side of vehicle-treated group) p = 0.0008 (vs. control side of each group)		one-way ANOVA followed by post-hoc Fisher's LSD test
		mirtazapine (5 mg/kg) mirtazapine (16 mg/kg)	6 6	p = 0.679 (vs. same side of vehicle-treated group) p = 0.0339 (vs. control side of each group) p = 0.196 (vs. same side of vehicle-treated group) n = 0.196 (vs. control side of each group)		
suppetitential fig. 5a	S100β & MT			p = 0.0651	F (5,35) = 2.347	
	control side lesioned side	vehicle mirtazapine (5 mg/kg) mirtazapine (16 mg/kg) vehicle mirtazapine (5 mg/kg) mirtazapine (5 mg/kg)	6 6 6 6 6 6			one-way ANOVA followed by post-hoc Fisher's LSD test
	GFAP			p < 0.0001	F (5,33) = 8.141	
	control side lesioned side	vehicle mirtazapine (5 mg/kg) mirtazapine (16 mg/kg) vehicle mirtazapine (5 mg/kg) mirtazapine (16 mg/kg)	6 6 6 6	p = 0.0041 (vs. same side of vehicle-treated group) p = 0.0056 (vs. same side of vehicle-treated group) p = 0.0056 (vs. control side of each group) p = 0.118 (vs. same side of vehicle-treated group) p = 0.1 (vs. same side of vehicle-treated group) p = 0.0868 (vs. same side of vehicle-treated group) p = 0.0858 (vs. control side of each group) p = 0.0853 (vs. control side of each group)		one-way ANOVA followed by post-hoc Fisher's LSD test
supplemental lig. 30	GFAP & MT			p = 0.00163	F (5,33) = 5.23	
	control side lesioned side	vehicle mirtazapine (5 mg/kg) mirtazapine (16 mg/kg) vehicle mirtazapine (5 mg/kg) mirtazapine (16 mg/kg)	6 6 6 6	p = 0.127 (vs. same side of vehicle-treated group) p = 0.0034 (vs. same side of vehicle-treated group) p = 0.0142 (vs. control side of each group) p = 0.679 (vs. control side of each group) p = 0.108 (vs. control side of each group) p = 0.0556 (vs. same side of vehicle-treated group) p = 0.0556 (vs. same side of vehicle-treated group) p = 0.019 (vs. control side of each group)		one-way ANOVA followed by post-hoc Fisher's LSD test
supplemental fig. 4				p < 0.0001	F (5,35) = 7.96	
	control 6-OHDA (50 μM)	control-NCM-ACM Mir(10 µM)-NCM-ACM Mir(10 µM)-NCM + WAY100635-ACM control-NCM-ACM Mir(10 µM)-NCM-ACM	6 6 6 6	$p = 0.836 \text{ (vs. control-NCM-ACM+6-OHDA (0 \muM) group)}p = 0.559 \text{ (vs. control-NCM-ACM+6-OHDA (0 \muM) group)}p = 0.0003 \text{ (vs. control-NCM-ACM+6-OHDA (0 \muM) group)}p = 0.0096 \text{ (vs. Mir (10 \muM)-NCM-ACM+6-OHDA (0 \muM) group)}p = 0.148 \text{ (vs. control-NCM-ACM+6-OHDA (50 \muM) group)}p = 0.007 \text{ (vs. Mir (10 \muM)-NCM + WAY-ACM+6-OHDA (0 \muM) group)}$		one-way ANOVA followed by post-hoc Fisher's LSD test
		Mir(10 µM)-NCM + WAY100635-ACM	6	n = 0.544 (vs. Mir (10 uM)-NCM-ACM+6-OHDA (50 uM) group)		